

## **ASX ANNOUNCEMENT**

### **ADMEDUS WINS THE 2016 AUSTRALIAN 'MANUFACTURER OF THE YEAR' AWARD**

- Admedus wins the major category of 'Manufacturer of the Year' at the 2016 Manufacturers' Monthly Endeavour Awards
- Admedus also awarded "Most Innovative Manufacturing Company"
- The annual Endeavour Awards recognise best practice in the Australian manufacturing industry
- Winners announced at a prestigious awards presentation gala dinner held in Sydney on Thursday 12 May

#### **Brisbane, Australia 13th May 2016**

Admedus has today announced that it was awarded 'Manufacturer of the Year' at the 2016 Manufacturers' Monthly Endeavour Awards dinner held in Sydney on Thursday, 12 May. Admedus was chosen from over 40 other finalists to take out the major award on the night.

Admedus was also awarded 'Most Innovative Manufacturing Company' for its work in the research, manufacture and export of its lead regenerative tissue product CardioCel<sup>®</sup>, which is undertaken at the Company's state-of-the-art bio-manufacturing facility in Malaga, Western Australia.

"We are extremely pleased to have been awarded Manufacturer of the Year and grateful to have been chosen from such a strong field. It is an honour to have our innovation and quality in manufacturing recognised by the industry," said Admedus Managing Director Mr Lee Rodne.

Admedus' state-of-the-art bio-manufacturing facility was officially opened in August 2014 in order to support global demand for the Company's lead regenerative tissue product CardioCel.

CardioCel is developed using a high-tech engineering process called ADAPT<sup>®</sup>, whereby scientists treat a piece of animal pericardium (the heart covering membrane) to remove all RNA, DNA and remnants of cells to produce an off-the-shelf, ready to use collagen bio-scaffold that functions like human tissue.

The Admedus bio-manufacturing facility is equipped with in-house research and development labs, which allows Admedus scientists to work closely with the manufacturing team to refine CardioCel, as well as develop and distribute a portfolio of regenerative tissue products for soft tissue repair in the future.

“Admedus continues to invest in our Malaga bio-manufacturing facility to ensure expanded production based on global demand for CardioCel, as well as refine and develop current processes to accommodate for new products and product improvements,” said Mr Rodne.

Brought to you by Australia’s leading magazine for the manufacturing industry, Manufacturers’ Monthly Endeavour Awards program celebrates and recognises the achievements of industry leaders in their drive to achieve ‘best practice’ in manufacturing.

Follow us:

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](http://www.facebook.com/pages/Admedus)

Website: [www.admedus.com](http://www.admedus.com)

Blog: [www.admedus.com/au/category/news/](http://www.admedus.com/au/category/news/)

**For more information, please contact:**

Dr Julian Chick | Chief Operating Officer | Admedus Limited  
Tel: +61 (0)8 9266 0100

**Media:**

Shevaun Cooper | PR Manager | Admedus Limited  
Tel: +61 (0) 417 985 599 | Email: [scooper@admedus.com](mailto:scooper@admedus.com)

**Media Europe**

FTI Consulting  
Simon Conway / Victoria Foster Mitchell  
Tel: +44 (0) 20 3727 1000  
[admedus@fticonsulting.com](mailto:admedus@fticonsulting.com)

**US Investor**

Rx Communications Group, LLC  
Melody A. Carey  
+1 917 322 2571  
[mcarey@rxir.com](mailto:mcarey@rxir.com)

**About Admedus Limited**

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution and bio-manufacturing.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on [www.admedus.com](http://www.admedus.com)